Citigroup
BXRX

Citigroup’s Baudax Bio, Inc. Common Stock BXRX Stock Holding History

Citigroup’s Portfolio BXRX Stock Details BXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1
Closed – – 6696
2022
Q2 		$0 Sell
1
-18
-95% -$841 ﹤0.01% 6935
2022
Q1 		$1K Buy
+19
New +$3.51K ﹤0.01% 6264
2020
Q2 		– Sell
-1
Closed -$5K – 7760
2020
Q1 		$5K Hold
1
– – ﹤0.01% 7287
2019
Q4 		$11K Buy
+1
New +$8.53K ﹤0.01% 7190

Other funds holding BXRX

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citigroup's BXRX Position: Q3 2022 in Review

Citigroup sold out of Baudax Bio, Inc. Common Stock (BXRX) in Q3 2022, closing a stake of 1 share.

Citigroup first reported a position in BXRX in Q4 2019 and held it in 4 quarters. The position peaked at $11K in Q4 2019. 20 funds tracked by Wall St. Rank hold BXRX as of Q3 2022.

  • Citigroup reported no remaining Baudax Bio, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Citigroup sold 1 Baudax Bio, Inc. Common Stock share in Q3 2022.
  • Citigroup first reported a position in Baudax Bio, Inc. Common Stock in Q4 2019 and held it in 4 quarters.
  • Citigroup's Baudax Bio, Inc. Common Stock position peaked at $11K in Q4 2019.
  • 20 funds tracked by Wall St. Rank held Baudax Bio, Inc. Common Stock as of Q3 2022.

Based on Citigroup's 13F filing for Q3 2022, filed 10 Nov 2022.